Drugs that contain Zilucoplan Sodium
1. Zilbrysq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11014965 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10435438 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10208089 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10106579 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| US10562934 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752190 | UCB INC | Modulators of complement activity |
Jun, 2035
(11 years from now) | |
| US10835574 | UCB INC | Modulators of complement activity |
Jun, 2035
(11 years from now) | |
| US11535650 | UCB INC | Modulation of complement activity |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 17, 2028 |
| Orphan Drug Exclusivity(ODE-446) | Oct 17, 2030 |
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of generalized myasthenia gravis (gmg) in an adult patient who is anti-acetylcholine receptor (achr) antibody positive by subcutaneous administration of c5 complement inhibitor zilucoplan
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
ZILBRYSQ family patents
